United Kingdom · Question · Written question
UIN 13097
Tixagevimab/cilgavimab: Clinical Trials
Original
Introduced
6 June 2022
Last action
14 June 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
14 June 2022
Summary
To ask the Secretary of State for Health and Social Care, with reference to the MHRA press release on Evusheld approved to prevent covid-19 in people whose immune response is poor, published on 17 March 2022, whether the NHS (a) has made and (b) plans to
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
6 June 2022
Written question
To ask the Secretary of State for Health and Social Care, with reference to the MHRA press release on Evusheld approved to prevent covid-19 in people whose immune response is poor, published on 17 March 2022, whether the NHS (a) has made and (b) plans to
Source: Commons
14 June 2022
Answer
The National Health Service and experts are evaluating all available evidence to inform decisions on Evusheld, including whether real world evaluation could improve our understanding of efficacy against new variants. In addition, the Antivirals and Therap...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-06-06/13097
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1467604
- uk · wq-1467604 · source updated 14 June 2022